<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679315</url>
  </required_header>
  <id_info>
    <org_study_id>2007-07-073</org_study_id>
    <nct_id>NCT00679315</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Alfuzosin for the Treatment of Voiding Dysfunction in Female</brief_title>
  <official_title>Efficacy and Safety of Alfuzosin for the Treatment of Non-neurogenic Voiding Dysfunction in Female: An 8 Week Prospective, Randomized Double Blind, Placebo-Controlled, Parallel Group Study (Phase Ⅱ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Handok Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Korean Urological Association</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy of Alfuzosin (10 mg, qd) in reducing the&#xD;
      score of International Prostate Symptom Score (IPSS) from baseline to 8 weeks of treatment in&#xD;
      female patients with voiding dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Trial design&#xD;
&#xD;
      Phase II, multi-center, randomized, double-blind, placebo-controlled, parallel group study to&#xD;
      evaluate the clinical efficacy and safety of alfuzosin (10mg, qd) from baseline to 8 weeks of&#xD;
      treatment in female patients with non-neurogenic voiding dysfunction.&#xD;
&#xD;
      Efficacy Assessment&#xD;
&#xD;
        1. Primary efficacy endpoint&#xD;
&#xD;
           Actual change in the score of IPSS from baseline to 8 weeks of treatment.&#xD;
&#xD;
        2. Secondary efficacy endpoint&#xD;
&#xD;
             -  IPSS parameters&#xD;
&#xD;
             -  Percent change in the score of IPSS from baseline to 4 and 8 weeks of treatment.&#xD;
&#xD;
             -  Actual and percent changes in the sub-scale of IPSS from baseline to 4 and 8 weeks&#xD;
                of treatment&#xD;
&#xD;
             -  Storage score: sum of questions 2, 4 and 7&#xD;
&#xD;
             -  Voiding score: sum of questions 1, 3, 5 and 6&#xD;
&#xD;
             -  Scored form of the Bristol Female Lower Urinary Tract Symptoms&#xD;
                (BFLUTS-SF)parameters&#xD;
&#xD;
             -  Actual and Percent change in BFLUTS-SF from baseline to 4 and 8 weeks of treatment.&#xD;
&#xD;
             -  Actual and percent changes in the sub-scale of BFLUTS-SF from baseline to 4 and 8&#xD;
                weeks of treatment&#xD;
&#xD;
                  -  BFLUTS-FS: sum scores F1-F4&#xD;
&#xD;
                  -  BFLUTS-VS: sum scores V1-V3&#xD;
&#xD;
                  -  BFLUTS-IS: sum scores I1-I5&#xD;
&#xD;
                  -  BFLUTS-sex: sum scores S1 &amp; S2&#xD;
&#xD;
             -  Uroflowmetry &amp; PVR parameters&#xD;
&#xD;
                  -  Numeric and percent changes from baseline to 4 and 8 weeks of treatment.&#xD;
&#xD;
                  -  Maximum flow rate (mL/s)&#xD;
&#xD;
                  -  Average flow rate (mL/s)&#xD;
&#xD;
                  -  Post-void residual urine (mL)&#xD;
&#xD;
                  -  Micturition diary parameters&#xD;
&#xD;
                  -  Change in mean number of micturitions per 24 hours at weeks 4 and 8 relative&#xD;
                     to baseline&#xD;
&#xD;
                  -  Percent change of micturitions per 24 hours at weeks 4 and 8 relative to&#xD;
                     baseline&#xD;
&#xD;
                  -  Change in mean number of nighttime micturitions per 24 hours at weeks 4 and 8&#xD;
                     relative to baseline&#xD;
&#xD;
                  -  Percent change of nighttime micturitions per 24 hours at weeks 4 and 8&#xD;
                     relative to baseline&#xD;
&#xD;
                  -  Change in mean number of urgency episodes per 24 hours at weeks 4 and 8&#xD;
                     relative to baseline (Urgency episodes are defined as those with Bladder&#xD;
                     Sensation Scale rating of ≥ 3 in the diary).&#xD;
&#xD;
                  -  Percent change of urgency episodes per 24 hours at weeks 4 and 8 relative to&#xD;
                     baseline&#xD;
&#xD;
                  -  Change in the mean and sum rating on the Bladder Sensation Scale at weeks 4&#xD;
                     and 8 relative to baseline&#xD;
&#xD;
                  -  Quality of life (QoL) parameters&#xD;
&#xD;
                  -  Change in Bother score of IPSS from baseline to 4 and 8 weeks of treatment.&#xD;
&#xD;
                  -  Change in QOL subscale scores of BFLUTS SF from baseline to 4 and 8 weeks of&#xD;
                     treatment&#xD;
&#xD;
                  -  BFLUTS-QoL: Sum scores QoL1-QoL5&#xD;
&#xD;
                  -  Patient Perception of Bladder Condition (PPBC)&#xD;
&#xD;
                  -  Change from baseline in PPBC after 8 weeks of double-blind treatment&#xD;
&#xD;
                  -  Benefit, Satisfaction, and Willingness to Continue (BSW) Questions&#xD;
&#xD;
                  -  Patient Perception of Treatment Benefit at week 8&#xD;
&#xD;
                  -  Patient Perception of Treatment Satisfaction at week 8&#xD;
&#xD;
                  -  Willingness to continue with treatment at week 8&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Actual change in the score of IPSS from baseline to 8 weeks of treatment.</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>IPSS parameters</measure>
    <time_frame>4 and 8 weeks of treatment.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BFLUTS-SF parameters</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Uroflowmetry &amp; PVR parameters</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Micturition diary parameters</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life parameters</measure>
    <time_frame>4 and 8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Perception of Bladder Condition</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Benefit, Satisfaction, and Willingness to Continue (BSW) Questions</measure>
    <time_frame>8 weeks of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Voiding Dysfunction</condition>
  <arm_group>
    <arm_group_label>Alpha blocker</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>alfuzosin hydrochloride XL 10mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alfuzosin hydrochloride XL 10mg</intervention_name>
    <description>One tablet to be taken daily after a meal before bedtime for 8 weeks.</description>
    <arm_group_label>Alpha blocker</arm_group_label>
    <other_name>Xatral® XL</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One tablet to be taken daily after a meal before bedtime for 8 weeks.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged ≥ 18&#xD;
&#xD;
          -  Have voiding symptoms as chief complaints over 3 months&#xD;
&#xD;
          -  IPSS symptom score ≥ 15&#xD;
&#xD;
          -  A peak flow rate &lt;12 mL/sec with a minimum voided volume of 100 mL and/or a postvoid&#xD;
             residual urine volume &gt;150 mL&#xD;
&#xD;
          -  Underwent pressure-flow study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who meet any of the following criteria are to be excluded from the study:&#xD;
&#xD;
          -  Neurogenic voiding dysfunction&#xD;
&#xD;
          -  Anatomic causes of bladder outlet obstruction&#xD;
&#xD;
          -  Perform physical examination in patients diagnosed as BOO in pressure-flow study by&#xD;
             urethral evaluation with 16 Fr urethral sound: if there is resistance to 16Fr sound,&#xD;
             it will be diagnosed as anatomical BOO and the patients can not participate in the&#xD;
             study.&#xD;
&#xD;
          -  Previous surgical procedures related to incontinence or cystocele&#xD;
&#xD;
          -  Pregnant or nursing women&#xD;
&#xD;
          -  Intake of medications and drugs affecting bladder function: alpha blocker,&#xD;
             anticholinergic&#xD;
&#xD;
          -  Anticholinergic drugs: Tolterodine, Oxybutynin, Propiverin, Trospium, Solifenacin,&#xD;
             SSRI including TCA&#xD;
&#xD;
          -  Cholinergic drug: Bethanechol&#xD;
&#xD;
          -  Any other blocker other than alfuzosin&#xD;
&#xD;
          -  patients can be enrolled after wash-out&#xD;
&#xD;
          -  Any positive urine culture had to be successfully treated before the recruitment.&#xD;
&#xD;
          -  Clinically significant ( ≥ Stamey grade II/III) stress incontinence as determined by&#xD;
             the investigator and confirmed for female patients by a cough provocation test.&#xD;
&#xD;
          -  Recurrent UTIs defined as having been treated for symptomatic UTIs ≥ 4 times in the&#xD;
             last year&#xD;
&#xD;
          -  Diagnosed or suspected interstitial cystitis&#xD;
&#xD;
          -  Patients with marked cystocele or other clinically significant pelvic prolapse.&#xD;
&#xD;
          -  Treatment within the 14 days preceding randomization, or expected to initiate&#xD;
             treatment during the study with:&#xD;
&#xD;
          -  Estrogen treatment started more than 2 months prior to inclusion will be allowed&#xD;
&#xD;
          -  Receipt of any electrostimulation or bladder training within the 14 days before&#xD;
             randomization, or expected to start such treatment during the study.&#xD;
&#xD;
          -  Hypersensitive to the study drug&#xD;
&#xD;
          -  Orthotopic hypotension or history of orthotopic hypotension&#xD;
&#xD;
          -  Intake of calcium channel blockers&#xD;
&#xD;
          -  Severe hepatic or renal dysfunctions&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyu-Sung Lee, Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Holy Family Hospital, The Catholic University of Korea</name>
      <address>
        <city>Kyonggi-do</city>
        <zip>420-717</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cheil General Hospital &amp; Women's Healthcare Center, College of Medicine, Kwandong University</name>
      <address>
        <city>Seoul</city>
        <zip>100-380</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Anam Hospital, College of Medicine, Korea University</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kangnam St. Mary's Hospital, The Catholic University of Korea</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center, Ulsan College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2013</verification_date>
  <study_first_submitted>May 14, 2008</study_first_submitted>
  <study_first_submitted_qc>May 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2008</study_first_posted>
  <last_update_submitted>June 7, 2013</last_update_submitted>
  <last_update_submitted_qc>June 7, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>KYU-SUNG LEE</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>female voiding dysfunction</keyword>
  <keyword>alpha adrenoreceptor antagonists</keyword>
  <keyword>IPSS or American Urological Association symptom index</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alfuzosin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

